Catapult Therapeutics announces treatment of first patient in phase I trial of CAP-100 for relapsed or refractory CLL
Lelystad, the Netherlands – November 22, 2021 – Catapult Therapeutics, a clinical-stage biopharmaceutical company developing novel cancer treatments, today announced …
Read more